2-(2-硝基-4-(3-硝基苯基氨基)苯基)乙酸乙酯 | 1033771-61-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(2-硝基-4-(3-硝基苯基氨基)苯基)乙酸乙酯
• 英文名称: ethyl 2-(2-nitro-4-(3-nitrophenylamino)phenyl)acetate
• 英文别名: [2-nitro-4-(3-nitrophenylamino)phenyl]acetic acid ethyl ester；Ethyl 2-(2-nitro-4-((3-nitrophenyl)amino)phenyl)acetate；ethyl 2-[2-nitro-4-(3-nitroanilino)phenyl]acetate
• CAS: 1033771-61-7
• 化学式: C₁₆H₁₅N₃O₆
• 分子量: 345.312
• InChiKey: WXAHMSXRJCLXPA-UHFFFAOYSA-N

物化性质

• 沸点：
  479.0±45.0 °C(Predicted)
• 密度：
  1.389±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  130
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-(2-硝基-4-(3-硝基苯基氨基)苯基)乙酸乙酯 在 palladium 10% on activated carbon 、 氢气 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-(3-((2-oxoindolin-6-yl)amino)phenyl)acetamide
  参考文献：
  名称：

  Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models

  摘要：

  Neurotrophins and their receptors (TRKs) play key roles in the development of the nervous system and the maintenance of the neural network. Accumulating evidence points to their role in malignant transformations, chemotaxis, metastasis, and survival signaling and may contribute to the pathogenesis of a variety of tumors of both neural and non-neural origin. By screening the GNF kinase collection, a series of novel oxindole inhibitors of TRKs were identified. Optimization led to the identification of GNF-5837 (22), a potent, selective, and orally bioavailable pan-TRK inhibitor that inhibited tumor growth in a mouse xenograft model derived from RIE cells expressing both TRKA and NGF. The properties of 22 make it a good tool for the elucidation of TRK biology in cancer and other nononcology indications.

  DOI：

  10.1021/ml200261d
• 作为产物：
  描述：

  2-硝基-4-溴苯乙酸 在 硫酸 、 palladium diacetate 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 生成 2-(2-硝基-4-(3-硝基苯基氨基)苯基)乙酸乙酯
  参考文献：
  名称：

  Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models

  摘要：

  Neurotrophins and their receptors (TRKs) play key roles in the development of the nervous system and the maintenance of the neural network. Accumulating evidence points to their role in malignant transformations, chemotaxis, metastasis, and survival signaling and may contribute to the pathogenesis of a variety of tumors of both neural and non-neural origin. By screening the GNF kinase collection, a series of novel oxindole inhibitors of TRKs were identified. Optimization led to the identification of GNF-5837 (22), a potent, selective, and orally bioavailable pan-TRK inhibitor that inhibited tumor growth in a mouse xenograft model derived from RIE cells expressing both TRKA and NGF. The properties of 22 make it a good tool for the elucidation of TRK biology in cancer and other nononcology indications.

  DOI：

  10.1021/ml200261d

文献信息

• COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
  申请人：Mi Yuan

  公开号：US20100168182A1

  公开（公告）日：2010-07-01

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly TrkA, TrkB, TrkC, PDGFR and c-kit.

  本发明提供了一种新型化合物类别，包括这种化合物的药物组成物和使用这种化合物治疗或预防与异常或失调的激酶活性有关的疾病或紊乱，特别是TrkA、TrkB、TrkC、PDGFR和c-kit的方法。
• WO2008/73480
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS FAISANT OFFICE D'INHIBITEURS DE KINASE
  申请人：IRM LLC

  公开号：WO2008073480A1

  公开（公告）日：2008-06-19

  [EN] The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly TrkA, TrkB, TrkC, PDGFR and c-kit.
  [FR] L'invention concerne une nouvelle classe de composés, des compositions pharmaceutiques comprenant de tels composés et des procédés d'utilisation de tels composés pour traiter et prévenir des maladies ou des troubles associés à une activité kinase anormale ou déréglée, en particulier trkA, trkB, trkC, PDGFR et c-kit.
• Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models
  作者：Pam Albaugh、Yi Fan、Yuan Mi、Fangxian Sun、Francisco Adrian、Nanxin Li、Yong Jia、Yelena Sarkisova、Andreas Kreusch、Tami Hood、Min Lu、Guoxun Liu、Shenlin Huang、Zuosheng Liu、Jon Loren、Tove Tuntland、Donald S. Karanewsky、H. Martin Seidel、Valentina Molteni

  DOI：10.1021/ml200261d

  日期：2012.2.9

  Neurotrophins and their receptors (TRKs) play key roles in the development of the nervous system and the maintenance of the neural network. Accumulating evidence points to their role in malignant transformations, chemotaxis, metastasis, and survival signaling and may contribute to the pathogenesis of a variety of tumors of both neural and non-neural origin. By screening the GNF kinase collection, a series of novel oxindole inhibitors of TRKs were identified. Optimization led to the identification of GNF-5837 (22), a potent, selective, and orally bioavailable pan-TRK inhibitor that inhibited tumor growth in a mouse xenograft model derived from RIE cells expressing both TRKA and NGF. The properties of 22 make it a good tool for the elucidation of TRK biology in cancer and other nononcology indications.